What patient factors prompt you to consider starting dupilumab in patients with COPD?

The factors I consider are recurrent exacerbations, symptoms despite triple therapy, and an eosinophil count that is greater than 300.

What is unclear is the decision regarding chronic azithromycin and/or roflumilast versus dupilumab. It looks like roflumilast was not allowed in the study, and appar...

I look at the history of exacerbations despite LABA/LAMA/ICS compliance.

Typically, I will consider dupilumab in COPD patients with elevated peripheral eosinophils (> 300) and recurrent exacerbations despite triple inhaled therapy. Active smoking status doesn't necessarily influence my decision, unless I feel that there is a good chance the patient may quit smoking in th...